ArticleEuropean clinical respiratory journal2025
Utilizing a three-dimensional printed additional nebulization chamber for colistin nebulization with a large diluent volume through a vibrating mesh nebulizer: proof of concept.
Article in European clinical respiratory journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The volume of colistimethate sodium (CMS) that can be administered in a single application using a vibrating mesh nebulizer (VMN) is related to the capacity of the nebulization chamber. This study designed and tested a nebulization chamber and assessed the effects of the diluent volume on colistin nebulization. Methods: A bench study was conducted to evaluate the performance of the nebulization chamber. A 7-day clinical scenario involving the nebulization of two diluent volumes of CMS (6 and 12 mL) was simulated. Each diluent volume was nebulized for seven consecutive days. Particle size and viscosity were analyzed for four diluent volumes of CMS (3 mL, 6 mL, 9 mL, and 12 mL). Results: After 7 consecutive days of nebulization, residual colistin crystals were observed in both diluent volumes, with a higher incidence in the 6-mL than in the 12-mL diluent volume. The VMN malfunctioned once on day 5 when using the 6 mL diluent volume. Nebulized colistin output was inversely correlated with diluent viscosity. Conclusion: The additional nebulization chamber facilitated the nebulization of a larger diluent volume of CMS in a single nebulization course. Larger diluent volumes resulted in fewer residual CMS crystals and lower diluent viscosity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.